Chemotherapy for advanced HER2-negative breast cancer: can one algorithm fit all?

Despite advances, MBC is still incurable, with a 5-year survival of 24%[1]. For this reason, it represents a challenging scenario, where the achievement of disease control, palliation of symptoms and maintenance of an acceptable quality of life (QoL) remain the major goals to achieve. However, the development of increasingly effective therapeutic strategies have also allowed an improvement in overall survival (OS) and the achievement of sustained NED status in a very small and favorable subset of patients[2].

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2h7UeP4
via IFTTT